Spyre Therapeutics (AGLE) Stock Forecast, Price Target & Predictions

AGLE Stock Forecast

Spyre Therapeutics stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

AGLE Analyst Ratings

Buy

According to 2 Wall Street analysts, Spyre Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AGLE stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 28, 2022	Wells Fargo	Equal-Weight	Overweight	Upgrade
Oct 27, 2022	Piper Sandler	Neutral	Overweight	Upgrade
Aug 09, 2022	Wells Fargo	Equal-Weight	Equal-Weight	Hold

Row per page

Go to

Spyre Therapeutics's last stock rating was published by Wells Fargo on Oct 28, 2022. The company Upgrade its AGLE rating from "Equal-Weight" to "Overweight".

Spyre Therapeutics Financial Forecast

Spyre Therapeutics Revenue Forecast

	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18	Jun 18	Mar 18	Sep 17	Jun 17	Mar 17	Sep 16	Jun 16	Mar 16
Revenue	-	-	-	-	-	$688.00K	$198.00K	$168.00K	$174.00K	$625.00K	$1.36M	$1.40M	$13.70M	-	-	-	-	-	-	-	$2.38M	$1.51M	$1.26M	$1.48M	$982.00K	$1.15M	$1.37M	$859.00K
Avg Forecast	$1.55M	$1.38M	$1.09M	$5.50M	$3.54M	$721.05K	$120.00K	$5.00M	$3.79M	$570.00K	$1.24M	$4.05M	$12.15M	$13.00M	$4.54M	$4.54M	$3.52M	$3.40M	$3.10M	$2.76M	$1.96M	$1.36M	$1.44M	$1.51M	$982.00K	$1.34M	$1.25M	$10.13M
High Forecast	$1.86M	$1.65M	$1.30M	$6.60M	$4.25M	$865.26K	$144.00K	$6.00M	$4.54M	$684.00K	$1.49M	$4.86M	$14.58M	$15.60M	$5.45M	$5.45M	$4.23M	$4.08M	$3.72M	$3.31M	$2.36M	$1.63M	$1.73M	$1.81M	$1.18M	$1.61M	$1.50M	$12.16M
Low Forecast	$1.24M	$1.10M	$868.50K	$4.40M	$2.83M	$576.84K	$96.00K	$4.00M	$3.03M	$456.00K	$993.46K	$3.24M	$9.72M	$10.40M	$3.63M	$3.63M	$2.82M	$2.72M	$2.48M	$2.21M	$1.57M	$1.08M	$1.16M	$1.21M	$785.60K	$1.08M	$1.00M	$8.11M
# Analysts	7	7	15	16	16	20	9	12	17	14	6	11	7	7	9	15	13	13	13	7	7	7	9	9	9	8	8	10
Surprise %	-	-	-	-	-	0.95%	1.65%	0.03%	0.05%	1.10%	1.10%	0.35%	1.13%	-	-	-	-	-	-	-	1.21%	1.11%	0.87%	0.98%	1.00%	0.85%	1.10%	0.08%

Spyre Therapeutics's average Quarter revenue forecast for Sep 23 based on 16 analysts is $3.54M, with a low forecast of $2.83M, and a high forecast of $4.25M. AGLE's average Quarter revenue forecast represents a 414.62% increase compared to the company's last Quarter revenue of $688.00K (Jun 23).

Spyre Therapeutics EBITDA Forecast

	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18	Jun 18	Mar 18	Sep 17	Jun 17	Mar 17	Sep 16	Jun 16	Mar 16
# Analysts	7	7	15	16	16	20	9	12	17	14	6	11	7	7	9	15	13	13	13	7	7	7	9	9	9	8	8	10
EBITDA	-	-	-	-	$-18.34M	$-159.25M	$-18.81M	$-18.78M	$-18.35M	$-22.05M	$-24.04M	$-19.87M	$-6.34M	$-17.86M	$-18.57M	$-21.39M	$-21.47M	$-17.91M	$-17.07M	$-11.84M	$-9.34M	$-8.05M	$-7.80M	$-6.57M	$-6.20M	$-6.20M	$-5.40M	$-4.52M
Avg Forecast	$-309.60K	$-275.20K	$-19.13M	$5.49M	$-16.17M	$-31.36M	$-20.46M	$4.99M	$-17.30M	$-24.79M	$-21.88M	$-18.50M	$9.05M	$12.71M	$-21.19M	$4.53M	$3.35M	$3.35M	$3.09M	$2.65M	$-7.37M	$-7.13M	$-8.80M	$-6.71M	$-6.20M	$-7.11M	$-4.88M	$-53.29M
High Forecast	$-371.52K	$-330.24K	$-15.30M	$6.58M	$-12.94M	$-25.09M	$-16.37M	$5.99M	$-13.84M	$-19.83M	$-17.50M	$-14.80M	$10.86M	$15.25M	$-16.95M	$5.44M	$4.02M	$4.02M	$3.71M	$3.18M	$-5.90M	$-5.71M	$-7.04M	$-5.37M	$-4.96M	$-5.69M	$-3.91M	$-42.63M
Low Forecast	$-247.68K	$-220.16K	$-22.95M	$4.39M	$-19.41M	$-37.63M	$-24.55M	$3.99M	$-20.76M	$-29.75M	$-26.26M	$-22.20M	$7.24M	$10.17M	$-25.43M	$3.63M	$2.68M	$2.68M	$2.47M	$2.12M	$-8.85M	$-8.56M	$-10.56M	$-8.05M	$-7.43M	$-8.53M	$-5.86M	$-63.95M
Surprise %	-	-	-	-	1.13%	5.08%	0.92%	-3.76%	1.06%	0.89%	1.10%	1.07%	-0.70%	-1.41%	0.88%	-4.72%	-6.41%	-5.35%	-5.52%	-4.47%	1.27%	1.13%	0.89%	0.98%	1.00%	0.87%	1.11%	0.08%

undefined analysts predict AGLE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Spyre Therapeutics's previous annual EBITDA (undefined) of $NaN.

Spyre Therapeutics Net Income Forecast

	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18	Jun 18	Mar 18	Sep 17	Jun 17	Mar 17	Sep 16	Jun 16	Mar 16
# Analysts	7	7	15	16	16	20	9	12	17	14	6	11	7	7	9	15	13	13	13	7	7	7	9	9	9	8	8	10
Net Income	-	-	-	-	$-40.11M	$-217.08M	$-18.42M	$-18.82M	$-18.23M	$-22.32M	$-24.43M	$-20.31M	$-6.83M	$-18.22M	$-18.73M	$-21.50M	$-21.57M	$-18.02M	$-17.17M	$-11.92M	$-9.41M	$-8.12M	$-7.87M	$-6.63M	$-6.25M	$-6.24M	$-5.43M	$-4.55M
Avg Forecast	$147.31M	$128.30M	$-19.48M	$-0.52	$-16.53M	$-31.88M	$-20.83M	$1.95	$-17.68M	$-25.20M	$-22.28M	$-18.91M	$-4.75	$-3.25	$-21.03M	$-0.71	$-14.00	$-12.50	$-12.50	$-10.25	$-7.43M	$-7.20M	$-8.88M	$-6.77M	$-6.25M	$-7.15M	$-4.91M	$-53.64M
High Forecast	$48.63M	$42.36M	$-15.58M	$-0.52	$-13.22M	$-25.51M	$-16.67M	$3.27	$-14.14M	$-20.16M	$-17.82M	$-15.13M	$-7.95	$-5.44	$-16.83M	$-0.85	$-23.42	$-20.91	$-20.91	$-17.15	$-5.95M	$-5.76M	$-7.10M	$-5.42M	$-5.00M	$-5.72M	$-3.93M	$-42.91M
Low Forecast	$246.44M	$214.66M	$-23.37M	$-0.52	$-19.83M	$-38.26M	$-25.00M	$0.65	$-21.21M	$-30.24M	$-26.74M	$-22.69M	$-1.57	$-1.07	$-25.24M	$-0.57	$-4.62	$-4.13	$-4.13	$-3.38	$-8.92M	$-8.64M	$-10.65M	$-8.12M	$-7.50M	$-8.57M	$-5.90M	$-64.36M
Surprise %	-	-	-	-	2.43%	6.81%	0.88%	-9632943.01%	1.03%	0.89%	1.10%	1.07%	1437894.74%	5605538.46%	0.89%	30274647.89%	1540928.57%	1441520.00%	1373360.00%	1162634.15%	1.27%	1.13%	0.89%	0.98%	1.00%	0.87%	1.11%	0.08%

Spyre Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AGLE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Spyre Therapeutics SG&A Forecast

	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18	Jun 18	Mar 18	Sep 17	Jun 17	Mar 17	Sep 16	Jun 16	Mar 16
# Analysts	7	7	15	16	16	20	9	12	17	14	6	11	7	7	9	15	13	13	13	7	7	7	9	9	9	8	8	10
SG&A	-	-	-	-	$8.58M	$12.06M	$5.23M	$5.08M	$6.95M	$7.67M	$8.82M	$6.84M	$6.82M	$6.35M	$4.46M	$4.34M	$4.31M	$3.82M	$3.27M	$3.31M	$2.93M	$2.88M	$3.02M	$2.36M	$2.36M	$2.06M	$2.45M	$1.83M
Avg Forecast	-	-	$7.03M	$5.49M	$5.57M	$10.96M	$7.52M	$4.99M	$5.95M	$8.67M	$8.05M	$6.37M	$9.05M	$12.71M	-	$4.53M	$3.35M	$3.35M	$3.09M	$2.65M	$2.31M	$2.56M	$3.40M	$2.41M	$2.36M	$2.37M	$2.21M	$21.59M
High Forecast	-	-	$8.44M	$6.58M	$6.68M	$13.15M	$9.03M	$5.99M	$7.14M	$10.40M	$9.66M	$7.64M	$10.86M	$15.25M	-	$5.44M	$4.02M	$4.02M	$3.71M	$3.18M	$2.77M	$3.07M	$4.09M	$2.90M	$2.84M	$2.84M	$2.66M	$25.90M
Low Forecast	-	-	$5.63M	$4.39M	$4.45M	$8.77M	$6.02M	$3.99M	$4.76M	$6.93M	$6.44M	$5.09M	$7.24M	$10.17M	-	$3.63M	$2.68M	$2.68M	$2.47M	$2.12M	$1.85M	$2.05M	$2.72M	$1.93M	$1.89M	$1.89M	$1.77M	$17.27M
Surprise %	-	-	-	-	1.54%	1.10%	0.69%	1.02%	1.17%	0.89%	1.10%	1.07%	0.75%	0.50%	-	0.96%	1.29%	1.14%	1.06%	1.25%	1.27%	1.13%	0.89%	0.98%	1.00%	0.87%	1.11%	0.08%

Spyre Therapeutics's average Quarter SG&A projection for Dec 23 is $5.49M, based on 16 Wall Street analysts, with a range of $4.39M to $6.58M. The forecast indicates a -36.08% fall compared to AGLE last annual SG&A of $8.58M (Sep 23).

Spyre Therapeutics EPS Forecast

	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Jun 21	Mar 21	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Sep 18	Jun 18	Mar 18	Sep 17	Jun 17	Mar 17	Sep 16	Jun 16	Mar 16
# Analysts	7	7	15	16	16	20	9	12	17	14	6	11	7	7	9	15	13	13	13	7	7	7	9	9	9	8	8	10
EPS	-	-	-	-	$-9.34	$-0.00	$-0.20	$-0.22	$-0.19	$-0.27	$-0.37	$-0.31	$-0.10	$-0.28	$-0.57	$-0.67	$-0.66	$-0.55	$-0.59	$-0.54	$-0.46	$-0.49	$-0.48	$-0.47	$-0.47	$-0.47	$-0.46	$-0.40
Avg Forecast	$1.54	$1.34	$1.58	$-27.68M	$-0.44	$-4.50	$-4.75	$-25.16M	$-6.00	$-6.50	$-8.75	$-7.25	$-8.89M	$-36.42M	$-16.25	$-22.88M	$-17.22M	$-16.34M	$-16.71M	$-9.79M	$-9.25	$-13.50	$-16.75	$-14.75	$-13.75	$-16.75	$-14.00	$-5.54
High Forecast	$0.51	$0.44	$0.52	$-33.22M	$-0.44	$-1.49	$-1.57	$-30.20M	$-1.98	$-2.15	$-2.89	$-2.39	$-10.67M	$-43.70M	$-5.37	$-27.45M	$-20.67M	$-19.61M	$-20.05M	$-11.75M	$-3.05	$-4.46	$-5.53	$-4.87	$-4.54	$-5.53	$-4.62	$-4.44
Low Forecast	$2.58	$2.25	$2.64	$-22.14M	$-0.44	$-7.53	$-7.95	$-20.13M	$-10.04	$-10.87	$-14.64	$-12.13	$-7.11M	$-29.13M	$-27.19	$-18.30M	$-13.78M	$-13.07M	$-13.37M	$-7.84M	$-15.48	$-22.59	$-28.02	$-24.68	$-23.00	$-28.02	$-23.42	$-6.65
Surprise %	-	-	-	-	21.23%	0.00%	0.04%	0.00%	0.03%	0.04%	0.04%	0.04%	0.00%	0.00%	0.04%	0.00%	0.00%	0.00%	0.00%	0.00%	0.05%	0.04%	0.03%	0.03%	0.03%	0.03%	0.03%	0.07%

According to undefined Wall Street analysts, Spyre Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AGLE previous annual EPS of $NaN (undefined).

Spyre Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
XLO	Xilio Therapeutics	$0.97	$7.00	621.65%	Buy
CTMX	CytomX Therapeutics	$0.86	$5.73	566.28%	Buy
TIL	Instil Bio	$24.87	$78.25	214.64%	Hold
NUVB	Nuvation Bio	$2.56	$6.75	163.67%	Buy
ELYM	Eliem Therapeutics	$5.11	$13.00	154.40%	Buy
ASMB	Assembly Biosciences	$15.84	$35.50	124.12%	Buy
BNTC	Benitec Biopharma	$9.58	$20.33	112.21%	Buy
DSGN	Design Therapeutics	$5.76	$9.67	67.88%	Buy
EWTX	Edgewise Therapeutics	$30.79	$45.00	46.15%	Buy
EFTR	eFFECTOR Therapeutics	-	$5.50	-	Buy
IKNA	Ikena Oncology	$1.68	$1.33	-20.83%	Buy
AGLE	Spyre Therapeutics	$12.01	$1.50	-87.51%	Buy

AGLE Forecast FAQ

Is Spyre Therapeutics a good buy?

Yes, according to 2 Wall Street analysts, Spyre Therapeutics (AGLE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of AGLE's total ratings.

What are Spyre Therapeutics's analysts' financial forecasts?

AGLE's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $9.88M (high $11.86M, low $7.9M), average EBITDA is $-62.506M (high $-47.81M, low $-77.202M), average net income is $-69.243M (high $-55.394M, low $-83.091M), average SG&A $29.54M (high $35.45M, low $23.63M), and average EPS is $-27.679M (high $-33.215M, low $-22.144M).

Did the AGLE's actual financial results beat the analysts' financial forecasts?

Based on Spyre Therapeutics's last annual report (Dec 2022), the company's revenue was $2.33M, which missed the average analysts forecast of $10.6M by -78.02%. Apple's EBITDA was $-84.781M, beating the average prediction of $-58.981M by 43.74%. The company's net income was $-83.815M, beating the average estimation of $-65.161M by 28.63%. Apple's SG&A was $28.53M, beating the average forecast of $27.65M by 3.17%. Lastly, the company's EPS was $-0.99, missing the average prediction of $-25.163M by -100.00%. In terms of the last quarterly report (Jun 2023), Spyre Therapeutics's revenue was $688K, missing the average analysts' forecast of $721.05K by -4.58%. The company's EBITDA was $-159M, beating the average prediction of $-31.362M by 407.76%. Spyre Therapeutics's net income was $-217M, beating the average estimation of $-31.882M by 580.88%. The company's SG&A was $12.06M, beating the average forecast of $10.96M by 10.04%. Lastly, the company's EPS was $-0.0023, missing the average prediction of $-4.5 by -99.95%